Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644545 | 0.87 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21131569 | 0.82 | TRPV4 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2648329 | 0.81 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2648034 | 0.80 | GABRA1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL28445916 | 0.79 | CYP11B1 (0.44) | CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL25471590 | 0.78 | CYP11B1 (0.36) | CYP11B1CYP11B2TRPV4MAOBMAOA | |
| SCHEMBL2652917 | 0.76 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2651669 | 0.76 | CYP11B1 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2652017 | 0.75 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2653493 | 0.75 | BIRC5 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485640-B2 | Imidazopyrazinones as GABA-A receptor anxiolytics | MERCK SHARP & DOHME LIMITED (GB) | 2009-02-03 | — | — | US | disclosed |
| US-7279580-B2 | Imidazo-pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | MERCK SHARP & DOHME LTD. (GB) | 2006-01-19 | — | — | US | disclosed |
| EP-1409488-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-6960598-B2 | (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. | 2005-11-01 | — | — | US | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-07-28 | — | — | US | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6900215-B2 | For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders | MERCK SHARP & DOHME LTD. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20030216395-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1343788-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-6617326-B2 | For therapy and prophylaxis of adverse conditions of the central nervous system, including anxiety and convulsions | MERCK SHARP & DOHME LTD. | 2003-09-09 | — | — | US | disclosed |
| US-20030055060-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-20 | — | — | US | disclosed |
| WO-2003008418-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003006464-A1 | (1,8) NAPHTHYRIDINES AS GABA LIGANDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002074772-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | GABRA1 2/4885GABRG2 15/4885GABRB3 8/4885 |
| US-20030216395-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | GABRA2, GABRA3, GABRA1 | GABRA1 3/4885GABRG2 14/4885GABRB3 8/4885 |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | GABRA1 5/4885GABRG2 15/4885GABRB3 6/4885 |
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRG2 22/4885GABRB3 11/4885 |
| US-20030055060-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | GABRA2, GABRA1, GABRA3 | GABRA1 2/4885GABRG2 15/4885GABRB3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.